1. Home
  2. NUAI vs RLMD Comparison

NUAI vs RLMD Comparison

Compare NUAI & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Era Energy & Digital Inc.

NUAI

New Era Energy & Digital Inc.

HOLD

Current Price

$6.74

Market Cap

633.1M

Sector

Energy

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$6.74

Market Cap

661.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUAI
RLMD
Founded
N/A
2004
Country
United States
United States
Employees
5
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
633.1M
661.9M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
NUAI
RLMD
Price
$6.74
$6.74
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$11.00
$12.40
AVG Volume (30 Days)
8.3M
1.3M
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.28
EPS
N/A
N/A
Revenue
N/A
$13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
154.83
52 Week Low
$0.32
$0.52
52 Week High
$9.45
$8.00

Technical Indicators

Market Signals
Indicator
NUAI
RLMD
Relative Strength Index (RSI) 69.98 50.77
Support Level $3.71 $5.66
Resistance Level $7.59 $7.46
Average True Range (ATR) 0.72 0.44
MACD 0.15 0.05
Stochastic Oscillator 87.33 73.31

Price Performance

Historical Comparison
NUAI
RLMD

About NUAI New Era Energy & Digital Inc.

New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: